Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (formerly Nasdaq: KRON) has generated a stream of news centered on its work as a biopharmaceutical and clinical-stage company focused on small molecule therapeutics that address deregulated transcription in cancer and autoimmune diseases. Company announcements describe how its proprietary discovery engine decodes transcription factor regulatory networks to identify druggable cofactors and support oncology and autoimmune programs.
News coverage for KRON has included scientific and pipeline updates, such as preclinical data from p300 lysine acetyltransferase (KAT) inhibitor programs in multiple myeloma, HPV-driven tumors, and autoimmune indications. Releases have detailed how p300 KAT inhibition can modulate pro-inflammatory signaling pathways, influence viral oncogene expression in HPV-driven tumor models, and support candidate selection for conditions such as Sjögren’s disease.
Corporate and strategic developments have also been prominent in Kronos Bio’s news flow. The company has reported decisions to discontinue development of a CDK9 inhibitor in a specific ovarian cancer setting, implement cost reduction strategies and workforce reductions, and evaluate strategic alternatives that could include acquisitions, mergers, or asset sales. These updates provide context on how Kronos Bio has managed its pipeline and resources.
A key news theme for KRON is the company’s acquisition by Concentra Biosciences, LLC. In May 2025, Kronos Bio announced a definitive merger agreement under which a Concentra subsidiary would launch a tender offer for all outstanding shares of Kronos Bio common stock for a cash payment per share plus a non-tradeable contingent value right tied to potential proceeds from specified product candidates and cost savings. A subsequent Form 8-K filed on June 20, 2025, reports that the tender offer was completed and the merger closed, with Kronos Bio becoming a wholly owned subsidiary of Concentra and its shares delisted from Nasdaq.
Investors, researchers, and observers reviewing KRON-related news can use this history to understand Kronos Bio’s scientific focus on deregulated transcription, the evolution of its pipeline, and the sequence of strategic decisions that culminated in its acquisition and delisting. This news archive offers a detailed record of how the company communicated scientific findings, financial results, restructuring measures, and corporate transactions over time.
Kronos Bio, Inc. (Nasdaq: KRON) announced the initiation of a Phase 1b/2 clinical trial for lanraplenib, a next-generation SYK inhibitor, in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). The trial will assess safety, pharmacokinetics, and anti-leukemic activity in combination with gilteritinib. This study is crucial as it aims to establish lanraplenib as a key treatment option for a significant patient population. Additionally, the company is advancing other investigational compounds, including entospletinib in a Phase 3 trial for NPM1-mutated AML and KB-0742 for MYC-amplified solid tumors.
Kronos Bio, Inc. has partnered with Invivoscribe to develop a companion diagnostic for their investigational therapy, entospletinib, aimed at treating NPM1-mutated acute myeloid leukemia (AML). This diagnostic will identify the presence of the NPM1 mutation in about one-third of AML patients and is critical for patient selection. The Phase 3 AGILITY trial is ongoing with expected efficacy data in late 2023. Both companies aim to submit the Premarket Approval application for the diagnostic alongside the New Drug Application for entospletinib.
Kronos Bio, Inc. (Nasdaq: KRON) has reported progress in its clinical programs, including the Phase 3 AGILITY trial for entospletinib targeting NPM1-mutated acute myeloid leukemia (AML). The company has $292.4 million in cash, expected to fund operations into Q4 2024. R&D expenses were $22.7 million with a net loss of $32.9 million, or $0.59 per share, for Q2 2022. Preclinical data presented at EHA congress supports the development of SYK inhibitors in genetically defined AML subsets. The company is also advancing its CDK9 inhibitor, KB-0742, and plans to announce a recommended Phase 2 dose soon.
Kronos Bio presented promising preclinical data on its SYK inhibitors, entospletinib and lanraplenib, at the European Hematology Association (EHA) 2022 Congress. These findings bolster support for targeting spleen tyrosine kinase (SYK) in genetically defined acute myeloid leukemia (AML) subsets. The Phase 3 AGILITY trial of entospletinib is exploring its efficacy alongside chemotherapy in NPM1-mutated AML, with data expected in late 2023. The research indicates potential anti-tumor activity and improved T-cell responses, highlighting a novel therapeutic mechanism.
Kronos Bio, Inc. (Nasdaq: KRON) will have President and CEO Norbert Bischofberger participate in investor conferences. Bischofberger will appear at the Jefferies Healthcare Conference on June 8, 2022, at 4:30 p.m. ET, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 3:20 p.m. PT. Live webcasts will be accessible on the Kronos Bio website, with replays available for 30 days post-event. Kronos Bio focuses on therapies for cancer treatment, notably developing entospletinib for NPM1-mutated AML and KB-0742 for MYC-amplified tumors.
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the H.C. Wainwright Global Investment Conference, with a webcast presentation scheduled for May 24, 2022, at 7 a.m. ET. This on-demand presentation will be accessible through their website, allowing investors to catch up after the event as a replay will be available for 30 days.
The company focuses on developing therapies for cancer, particularly through their investigational treatment, entospletinib, targeting NPM1-mutated acute myeloid leukemia.
Kronos Bio, Inc. (Nasdaq: KRON) announced the presentation of preclinical data on its investigational SYK inhibitors, entospletinib and lanraplenib, at the European Hematology Association 2022 Congress. The Phase 3 AGILITY study of entospletinib in NPM1-mutated acute myeloid leukemia (AML) is underway, with results expected in late 2023. Lanraplenib is being tested in a Phase 1b/2 study for relapsed/refractory AML. Key findings indicate strong predictive markers for entospletinib's efficacy and synergistic effects with other targeted therapies. The company aims to advance its pipeline amid challenging market conditions.
Kronos Bio, Inc. (Nasdaq: KRON) announced its first quarter 2022 financial results and business updates, reporting a net loss of $36.3 million or $0.65 per share. The company has $315.4 million in cash and investments, ensuring a financial runway into the second half of 2024. Progress was made on three clinical programs, including the CDK9 inhibitor KB-0742, with preclinical data presented at AACR supporting its efficacy in various cancers. The company also opened additional sites for the SYK inhibitor clinical trial and plans to announce further data in Q4 2022.
Kronos Bio has showcased preclinical data on KB-0742, a selective CDK9 inhibitor, at the AACR Annual Meeting 2022. The data suggest its potential efficacy against triple-negative breast, ovarian, and small-cell lung cancers, as well as lymphoma and other rare tumors. The company is advancing its Phase 1/2 clinical trial, which began enrolling patients in February 2021, with additional results expected in Q4 2022. A new liquid biopsy assay is also being presented to evaluate patient responses. These findings support future development stages for KB-0742.
Kronos Bio (Nasdaq: KRON) is set to present preclinical data on its CDK9 inhibitor, KB-0742, at the AACR Annual Meeting 2022. This includes findings from studies on MYC-amplified cancers such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. The ongoing Phase 1/2 trial has yielded preliminary positive data, with the company expected to announce the recommended Phase 2 dose by Q4 2022. Additionally, the research features a liquid biopsy assay to monitor patient responses. The poster presentations will take place on April 12 and April 10, 2022, in New Orleans.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
